On Wednesday 15 July at 17.00 (CEST) in collaboration with SIAARTI (Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care) we are supporting the WEBINAR entitled ” Extracorporeal Adsorptive Therapies in the Patient with Sepsis and COVID-19”.
On July 1, 2020 in collaboration with SMART (Smart Meeting Anesthesia Resuscitation Intensive Care) we are hosting the WEBINAR entitled “Minimally Invasive CO2 Removal: From Theory to Practice” with a panel of world-reknown experts.
COVID-19 patients typically present with fever and respiratory symptoms, but some patients also show gastrointestinal symptoms such as diarrhea, vomiting and abdominal pain at admission or developed during hospitalization.
A recent study shows that endotoxemia is often found in the blood of patients with COVID-19 pneumonia, indicating that loss of intestinal barrier function significantly contributes to the pathogenesis of COVID-19.
In a recent review published in the journal Blood Purification, a panel of world-renowned experts discusses the role of extracorporeal blood purification and organ support in the critically ill patient affected by COVID-19. The panel provides an expert review and recommendation including indications for Polymyxin B Hemoperfusion (Toraymyxin®)
Toraymyxin® has already been used to treat severe unresponsive COVID-19 patients in Europe, Russia, Asia and the U.S. Considering the current knowledge of the pathophysiology of COVID-19 and similar viral infections, it is rational to consider a role of Polymyxin B Hemoperfusion as an additional therapy in unresponsive patients affected by COVID-19.
Spectral Medical Inc announces in a press release on April 20th 2020 that Health Canada has issued an Interim Order expanding the already approved indications for use of the Toraymyxin medical device specifically for patients with COVID-19, particularly those with severe acute respiratory failure.
Spectral Medical Inc announces in a press release on April 14th 2020 that the US FDA (Food and Drug Administration) has approved an Investigational Device Exemption (IDE) for the medical device Toraymyxin to treat COVID-19 patients suffering from septic shock.
It is rational to consider a hemodialysis strategy that is effective as renal support treatment while at the same time providing immunoprotection and immunomodulation through the removal of inflammatory mediators generated by immune cells involved in the advancement of the disease.
In a recent Spotlight article published in The Lancet Respiratory Medicine Claudio Ronco, Paolo Navalesi and Jean Louis Vincent discuss the possible role of extracorporeal organ support therapies in the intensive care unit during a viral outbreak, like the current COVID-19.
W have summarized the clinical experiences currently available in literature with the use of Polymyxin B hemoperfusion in patients with viral infection (H1N1-H5N1 influenza) who developed severe pneumonia or ARDS.